$63.94
Value $205M
PDEX and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$63.94
Value $205M
$349.91
Value $318B
Pro-Dex (PDEX) has a market value of $205M and UnitedHealth (UNH) $318B. Over the last year, with dividends, PDEX moved +109.9% and UNH +12.1%. The P/E is 17.0 for PDEX and 20.0 for UNH. Dividend yield: PDEX none, UNH 2.59%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
PDEX$205M
UNH$318B
UNH is 1,551 times PDEX
Revenue, 12 months
PDEX$80M
UNH$450B
UNH is 5,651 times PDEX
Net income, 12 months
PDEX$12M
UNH$15.9B
UNH is 1,320 times PDEX
Operating margin
PDEX16.8%
UNH5.3%
11.5 points apart
ROIC
PDEX17.4%
UNH11.3%
6.1 points apart
P/E
PDEX17.0
UNH20.0
UNH is 1.2 times PDEX
Dividend yield
PDEX0.0%
UNH2.6%
2.6 points apart
5-year return
PDEX+204.5%
UNH-14.7%
219.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
PDEX+204.5%
UNH-14.7%
| Period | PDEXWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +109.9%Price +109.9% | +12.1%Price +9.2% |
| 3 years since November 17, 2023 | +273.9%+55.2% a yearPrice +273.9% | -30.5%-11.4% a yearPrice -34.8% |
| 5 years since November 17, 2021 | +204.5%+24.9% a yearPrice +204.5% | -14.7%-3.1% a yearPrice -22.1% |
| 10 years since November 18, 2016 | +1,353.2%+30.7% a yearPrice +1,353.2% | +176.5%+10.7% a yearPrice +134.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
PDEXPro-DexUNHUnitedHealth
| Price | $63.94 | $349.91 |
|---|---|---|
| Market value | $205M | $318B |
| Enterprise value (EV) | $208M | $363B |
| P/E | 17.0 | 20.0 |
| P/E, 5-year median | 14.2 | 25.0 |
| P/B | 4.2 | 3.1 |
| EV/EBIT | 15.6 | 15.2 |
| Free cash flow yield | 5.2% | 7.2% |
| Revenue, 12 months | $80M | $450B |
|---|---|---|
| Net income, 12 months | $12M | $15.9B |
| Free cash flow, 12 months | $11M | $22.8B |
| Earnings per share, 12 months | $3.63 | $17.52 |
| Revenue growth, year on year | 16.5% | 11.8% |
| Revenue growth a year, past | +15.3%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | +21.3%over 5 years | -3.8%over 5 years |
| Gross margin | 32.5% | 88.3% |
|---|---|---|
| Operating margin | 16.8% | 5.3% |
| Net margin | 15.1% | 3.5% |
| ROIC | 17.4% | 11.3% |
| ROE | 26.7% | 15.5% |
| Cash | $13M | $28.5B |
|---|---|---|
| Total debt | $19M | $74.3B |
| Net debt / EBITDA | 0.2 | 1.6 |
| Interest cover | 15.4× | 6.2× |
| Dividend yield | – | 2.6% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | 1.7% | 1.8% |
| Shareholder yield | 1.7% | 4.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($318B) is about 1,550.6 times Pro-Dex ($205M), at today's prices.
Since November 18, 2016, PDEX's price moved +1,353.2% and UNH's +134.1%. With dividends: PDEX +1,353.2% (+30.7% a year), UNH +176.5% (+10.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Pro-Dex and 2.59% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
At today's price, the P/E is 17.0 for PDEX and 20.0 for UNH. The median of the last five years was 14.2 and 25.0, which shows where each stands against its own past.
Over the last twelve months, the net margin was 15.1% for Pro-Dex and 3.5% for UnitedHealth, and the operating margin 16.8% and 5.3%. Revenue was $80M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.